Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
JP Morgan analyst Jessica Fye maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and raises the price target from...
FDA extends review of Denali Therapeutics' tividenofusp alfa for Hunter syndrome to April 2026; analysts remain confident i...
Denali Therapeutics Inc. (NASDAQ:DNLI) today announced that the U.S. Food and Drug Administration (FDA) has extended its review...
Cantor Fitzgerald analyst Josh Schimmer reiterates Denali Therapeutics (NASDAQ:DNLI) from Overweight to Overweight.
Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and lowers the price t...
Denali Therapeutics (NASDAQ:DNLI) reported quarterly losses of $(0.72) per share which missed the analyst consensus estimate of...
FDA assigns PDUFA target action date of January 5, 2026, for decision on accelerated approvalTividenofusp alfa is designed to d...
B of A Securities analyst Tazeen Ahmad maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and lowers the price target fr...
